{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:57:58Z","timestamp":1787133478639,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"DOI":"10.7759\/cureus.40139","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T17:50:41Z","timestamp":1686246641000},"source":"Crossref","is-referenced-by-count":5,"title":["Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV"],"prefix":"10.7759","author":[{"given":"Prarthana R","family":"Mahale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijalkumar S","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navsin","family":"Kasmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5897\/jahr2020.0512","article-title":"Treatment outcomes of tenofovir versus zidovudine-based first-line antiretroviral therapy regimens at Zewditu Memorial Hospital: a retrospective cohort study","volume":"12","author":"Terefe A","year":"2020","unstructured":"Terefe A, Feyissa M, Shibeshi W. Treatment outcomes of tenofovir versus zidovudine-based first-line antiretroviral therapy regimens at Zewditu Memorial Hospital: a retrospective cohort study. JAHR. 2020, 12:45-54. 10.5897\/jahr2020.0512","journal-title":"JAHR"},{"key":"ref2","unstructured":"National AIDS Control Organization. (2019). Accessed. February 15, 2022: https:\/\/naco.gov.in\/sites\/default\/files\/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002285","article-title":"Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients","volume":"33","author":"Radford M","year":"2019","unstructured":"Radford M, Parks DC, Ferrante S, Punekar Y. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS. 2019, 33:1739-49. 10.1097\/QAD.0000000000002285","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002254","article-title":"Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir","volume":"33","author":"Meireles MV","year":"2019","unstructured":"Meireles MV, Pascom AR, Duarte EC, McFarland W. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. AIDS. 2019, 33:1663-8. 10.1097\/QAD.0000000000002254","journal-title":"AIDS"},{"key":"ref5","unstructured":"DHHSPanel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. (2022). Accessed: February 11, 2022: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/AdultandAdolescentGL_2021_08_16.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06851-9","article-title":"Patient experiences of switching from efavirenz- to dolutegravir-based antiretroviral therapy: a qualitative study in Uganda","volume":"21","author":"Twimukye A","year":"2021","unstructured":"Twimukye A, Laker M, Odongpiny EA, et al.. Patient experiences of switching from efavirenz- to dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect Dis. 2021, 21:1154. 10.1186\/s12879-021-06851-9","journal-title":"BMC Infect Dis"},{"key":"ref7","unstructured":"WHO recommends Dolutegravir as preferred hiv treatment option in all populations. (2019). Accessed. February 15, 2022: https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populat...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel DA","year":"2014","unstructured":"Patel DA, Snedecor SJ, Tang WY, et al.. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PLoS One. 2014, 9:e105653. 10.1371\/journal.pone.0105653","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis","volume":"19","author":"Snedecor SJ","year":"2019","unstructured":"Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019, 19:484. 10.1186\/s12879-019-3975-6","journal-title":"BMC Infect Dis"},{"key":"ref10","article-title":"Systematic literature review and network meta-analysis assessing first-line antiretroviral treatments","author":"Kanters S","year":"2018","unstructured":"Kanters S, Jansen J, Zoratti M, Forrest J, Humphries B, Campbell J. Systematic literature review and network meta-analysis assessing first-line antiretroviral treatments. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.  World Health Organization, Geneva; 2018."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.17352\/2455-5479.000052","article-title":"Immunological outcomes between tenofovir versus zidovudine-based regimens: a retrospective cohort study","volume":"5","author":"Lugoba M","year":"2019","unstructured":"Lugoba M, Kilonzi M, Bwire G. Immunological outcomes between tenofovir versus zidovudine-based regimens: a retrospective cohort study. Arch Community Med Public Health. 2019, 5:43-8. 10.17352\/2455-5479.000052","journal-title":"Arch Community Med Public Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters S","year":"2020","unstructured":"Kanters S, Vitoria M, Zoratti M, et al.. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020, 28:100573. 10.1016\/j.eclinm.2020.100573","journal-title":"EClinicalMedicine"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162775","article-title":"Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review","volume":"11","author":"Rutherford GW","year":"2016","unstructured":"Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review. PLoS One. 2016, 11:e0162775. 10.1371\/journal.pone.0162775","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi K","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, et al.. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020, 70:1267-74. 10.1093\/cid\/ciz407","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S316776","article-title":"Virological suppression and its associated factors of dolutegravir based regimen in a resource-limited setting: an observational retrospective study in Ethiopia","volume":"13","author":"Mehari EA","year":"2021","unstructured":"Mehari EA, Muche EA, Gonete KA. Virological suppression and its associated factors of dolutegravir based regimen in a resource-limited setting: an observational retrospective study in Ethiopia. HIV AIDS (Auckl). 2021, 13:709-17. 10.2147\/HIV.S316776","journal-title":"HIV AIDS (Auckl)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525","article-title":"Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens","volume":"76","author":"Norwood J","year":"2017","unstructured":"Norwood J, Turner M, Bofill C, et al.. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017, 76:527-31. 10.1097\/QAI.0000000000001525","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S347054","article-title":"Comparison of renal function biomarkers of serum creatinine and cystatin C in HIV-infected people on dolutegravir-containing therapy","volume":"15","author":"Lu L","year":"2022","unstructured":"Lu L, Li X, Liu X, et al.. Comparison of renal function biomarkers of serum creatinine and cystatin C in HIV-infected people on dolutegravir-containing therapy. Infect Drug Resist. 2022, 15:1695-706. 10.2147\/IDR.S347054","journal-title":"Infect Drug Resist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff J","year":"2013","unstructured":"Koteff J, Borland J, Chen S, et al.. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013, 75:990-6. 10.1111\/j.1365-2125.2012.04440.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/156937-treatment-outcomes-of-dolutegravir--versus-efavirenz-based-highly-active-antiretroviral-therapy-regimens-among-treatment-naive-people-living-with-hiv","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:33Z","timestamp":1707508893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/156937-treatment-outcomes-of-dolutegravir--versus-efavirenz-based-highly-active-antiretroviral-therapy-regimens-among-treatment-naive-people-living-with-hiv"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.40139","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}